Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average recommendation of “Hold” from the twenty-five analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $60.88.

A number of brokerages have recently issued reports on SRPT. Deutsche Bank Aktiengesellschaft decreased their target price on Sarepta Therapeutics from $50.00 to $25.00 and set a “hold” rating on the stock in a research report on Tuesday, June 17th. Oppenheimer decreased their target price on Sarepta Therapeutics from $123.00 to $45.00 and set an “outperform” rating on the stock in a research report on Friday, June 20th. William Blair reiterated a “market perform” rating on shares of Sarepta Therapeutics in a research report on Friday, June 20th. Wells Fargo & Company decreased their target price on Sarepta Therapeutics from $100.00 to $75.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 17th. Finally, TD Cowen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 price objective for the company. in a research note on Wednesday, June 18th.

Sarepta Therapeutics Trading Up 0.6%

Sarepta Therapeutics stock opened at $18.98 on Wednesday. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a 12 month low of $18.30 and a 12 month high of $164.52. The stock’s 50 day simple moving average is $41.67 and its two-hundred day simple moving average is $81.09. The firm has a market cap of $1.87 billion, a PE ratio of -7.06 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. During the same quarter in the prior year, the company posted $0.73 EPS. The company’s revenue for the quarter was up 80.2% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Exchange Traded Concepts LLC purchased a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $479,000. GAMMA Investing LLC boosted its stake in shares of Sarepta Therapeutics by 4,682.8% in the 1st quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company’s stock valued at $2,607,000 after buying an additional 39,991 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Sarepta Therapeutics by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock valued at $75,842,000 after buying an additional 12,000 shares during the period. Proficio Capital Partners LLC purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $3,829,000. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 145 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.